People who order low-cost versions of the wildly popular weight-loss drugs Wegovy and Zepbound from so-called compounding pharmacies might soon see disruptions in their medication
In its lawsuit, the OFA said that the FDAs decision to end the shortage was a reckless and arbitrary move and could deprive patients of a vital treatment for type 2 diabetes and obesity. In an interview with BioSpace last month, David Rosen, partner at Foley & Lardner, said that the lawsuit is a precedent in this area. Prior to the OFA suit, no one has ever challenged the FDAs decision to remove a therapy from the drug shortage list. The OFA case is still ongoing, with the next court update due on Thursday
A common pattern (exact brands and steps vary): Semaglutide: start low for 4 weeks, then step up every 4+ weeks toward a target dose if tolerated
Tercero , retrasan el vaciamiento gstrico, lo que significa que los alimentos permanecen ms tiempo en el estmago, reduciendo los picos de glucosa despus de las comidas
The pharmacy doing the actual compounding determines the quality of what ends up in your vial
Patients with a personal or family history of medullary thyroid carcinoma or MEN2 should discuss this with their clinical team before enrolling in any trial involving this drug class
